Literature DB >> 35739076

Peripheral artery disease independently associated with significantly higher risk for COVID-19 mortality: Evidence based on adjusted effect estimates.

Jiahao Ren1, Yuqing Hao2, Lan Nan3, Yadong Wang4, Haiyan Yang1.   

Abstract

OBJECTIVE: To investigate the influence of peripheral artery disease (PAD) on the risk of mortality among coronavirus disease 2019 (COVID-19) patients based on adjusted effect estimates.
METHODS: Systematic searches were performed through electronic databases. A random-effect model was applied to calculate the pooled effect and corresponding 95% confidence interval (CI). Inconsistency index (I2) was used to evaluate the heterogeneity across studies. Sensitivity analysis, subgroup analysis, and Begg's test were all implemented.
RESULTS: On the basis of 16 eligible studies with 142,832 COVID-19 patients, the meta-analysis showed that PAD significantly increased the risk for mortality among COVID-19 patients (pooled effect = 1.29, 95% CI: 1.10-1.51). The significant association was also observed in the subgroup analysis stratified by hospitalized patients, mean age ≥ 60 years, Europe and North America. Sensitivity analysis verified the robustness of our findings. Begg's test (P = 0.15) showed there was no potential publication bias.
CONCLUSIONS: COVID-19 patients with PAD may have a greater risk of mortality. Clinicians and nursing staff are supposed to identify and monitor these high-risk patients in a timely manner and provide appropriate clinical treatment for them.

Entities:  

Keywords:  COVID-19; Peripheral artery disease; meta-analysis; mortality

Year:  2022        PMID: 35739076      PMCID: PMC9234371          DOI: 10.1177/17085381221111226

Source DB:  PubMed          Journal:  Vascular        ISSN: 1708-5381            Impact factor:   1.105


Recently, Zuin et al.[1] have published a meta-analysis in this journal and indicated that peripheral artery disease (PAD) was significantly associated with a two-fold greater risk of death of coronavirus disease 2019 (COVID-19) patients. This is an interesting study. However, the conclusion was summarized on the basis of unadjusted effect estimates without controlling potential confounders. To our knowledge, several covariates such as age, sex, and comorbidities markedly affect the clinical outcome of COVID-19,[2,3] which may modulate the relationship between PAD and COVID-19 mortality. For instance, Li et al.[4] performed a univariate analysis and revealed that PAD was correlated with significant higher mortality risk of COVID-19 while the significant association was not observed in the multivariate analysis. Besides, the adjusted correlation reported across individual studies have not been consistent.[5-8] Therefore, it is an urgent need to perform an updated meta-analysis based on risk factors-adjusted effects to clarify this association. A systematical literature retrieval was carried out among several electronic databases including Web of Science, Scopus, PubMed, Wiley, Springer and Elsevier ScienceDirect to recognize all eligible studies published as of 7 May 2022 using the following keywords: “COVID-19,” “SARS-CoV-2,” “peripheral artery disease,” and “mortality.” Only peer-reviewed articles published in English investigating the risk factor-adjusted association between PAD and COVID-19 mortality were enrolled. Heterogeneity was measured by inconsistency index (I2). A random-effects model was applied to calculate the pooled effect and 95% confidence interval (CI). Sensitivity analysis was performed to check the stability of our study. Begg’s test was conducted to evaluate the publication bias. Statistical analyses were conducted on R software (Version 4.1.2). All reported p-values are two-tailed and p ≤ 0.05 indicated statistical significance. Totally, 16 eligible studies including 142,832 cases were enrolled in this meta-analysis (Table 1). This meta-analysis indicated that PAD was significantly associated with a higher risk for mortality in COVID-19 patients (pooled effect = 1.29, 95% CI: 1.10–1.51; Figure 1(a)). When the participants were only limited to hospitalized COVID-19 patients, PAD was still significantly associated with a higher risk for COVID-19 mortality (pooled effect = 1.37, 95% CI: 1.14–1.64). The significant association was also observed in studies with mean age ≥ 60 years (pooled effect = 1.35, 95% CI: 1.13–1.60), Europe (pooled effect = 1.19, 95% CI: 1.01–1.41) and North America (pooled effect = 1.55, 95% CI: 1.18–2.03). Sensitivity analysis verified the stability and robustness of our results (Figure 1(b)). Begg’s test showed that there was no publication bias (p = 0.15, Figure 1(c)).
Table 1.

Basic characteristics of the included studies.

AuthorCountrySettingSample sizeAgeMale (%)Adjusted effect estimate (95%CI)
Tanboğa IHTurkeyHospitalized60,98049 (36–63)53.00.85 (0.71–1.01)
Gonzalez-fajardo JASpainHospitalized10665.66 ± 15.4967.97.476 (1.634–34.202)
Girardin JLUSAHospitalized421061.89 ± 18.8258.11.33 (1.05–1.69)
Li WChinaHospitalized112558.3 ± 15.149.90.76 (0.18–3.25)
Caro-codón JSpainHospitalized91863.2 ± 15.560.11.84 (1.08–3.12)
Scoccia AItalyHospitalized162569 (58–77)67.22.03 (1.19–3.67)
Cummins LUKHospitalized1,78159.255.21.37 (0.74–2.52)
Budweiser SGermanyHospitalized52673 (57–82)53.41.42 (0.52–4.31)
Cai MUSAAll patients49,23863.3 (49.8–73.1)88.51.09 (0.92–1.29)
Rieder MGermanyAll patients1,43371.30 ± 13.2960.20.80 (0.48–1.32)
Marquès MSpainHospitalized2,11266.55 ± 17.7457.11.33 (0.81–2.14)
Kikuchi KJapanHospitalized1,0108070.21.49 (1.05–2.10)
Poli DItalyHospitalized1,09171 (59–82)59.94.90 (1.60–15.10)
Palaiodimos LUSAHospitalized8,83362 (49–74)59.30.939 (0.676–1.305)
Smolderen KGUSAHospitalized3,83063.1 ± 18.449.51.45 (1.11–1.88)
Piskač živković NCroatiaHospitalized4,01474 (64–82)56.21.40 (1.08–1.80)

Notes: CI, confidence interval.

Figure 1.

(A) Forest plot indicated the significant association between peripheral artery disease (PAD) and higher risk for mortality of coronavirus disease 2019 (COVID-19) patients; (B) Sensitivity analysis exhibited the stability of the overall result; (C) Funnel plot showed no potential publication bias.

Basic characteristics of the included studies. Notes: CI, confidence interval. (A) Forest plot indicated the significant association between peripheral artery disease (PAD) and higher risk for mortality of coronavirus disease 2019 (COVID-19) patients; (B) Sensitivity analysis exhibited the stability of the overall result; (C) Funnel plot showed no potential publication bias. In conclusion, this current meta-analysis on the basis of adjusted effect sizes indicated that PAD was independently associated with a significantly higher risk for COVID-19 mortality. We hope our present findings will contribute to more accurate elaboration and substantiation of the data reported by Zuin et al.
  8 in total

1.  Prevalence of pre-existing peripheral artery disease in COVID-19 patients and relative mortality risk: Systematic review and meta-analysis.

Authors:  Marco Zuin; Gianluca Rigatelli; Marco J Bilato; Claudio Bilato; Loris Roncon
Journal:  Vascular       Date:  2022-05-20       Impact factor: 1.105

2.  Factors associated with COVID-19 related hospitalisation, critical care admission and mortality using linked primary and secondary care data.

Authors:  Lisa Cummins; Irene Ebyarimpa; Nathan Cheetham; Victoria Tzortziou Brown; Katie Brennan; Jasmina Panovska-Griffiths
Journal:  Influenza Other Respir Viruses       Date:  2021-05-04       Impact factor: 5.606

3.  The association of hypertension with the severity and mortality of COVID-19 patients: Evidence based on adjusted effect estimates.

Authors:  Xuan Liang; Li Shi; Ying Wang; Wenwei Xiao; Guangcai Duan; Haiyan Yang; Yadong Wang
Journal:  J Infect       Date:  2020-06-25       Impact factor: 6.072

4.  Asthma in patients with coronavirus disease 2019: A systematic review and meta-analysis.

Authors:  Li Shi; Jie Xu; Wenwei Xiao; Ying Wang; Yuefei Jin; Shuaiyin Chen; Guangcai Duan; Haiyan Yang; Yadong Wang
Journal:  Ann Allergy Asthma Immunol       Date:  2021-02-18       Impact factor: 6.347

5.  Risk factors for systemic and venous thromboembolism, mortality and bleeding risks in 1125 patients with COVID-19: relationship with anticoagulation status.

Authors:  Wencheng Li; Zhifeng Xu; Huiling Xiang; Chun Zhang; Yutao Guo; Jing Xiong
Journal:  Aging (Albany NY)       Date:  2021-03-26       Impact factor: 5.682

6.  Impact of clinical and subclinical coronary artery disease as assessed by coronary artery calcium in COVID-19.

Authors:  Alessandra Scoccia; Guglielmo Gallone; Alberto Cereda; Anna Palmisano; Davide Vignale; Riccardo Leone; Valeria Nicoletti; Chiara Gnasso; Alberto Monello; Arif Khokhar; Alessandro Sticchi; Andrea Biagi; Carlo Tacchetti; Gianluca Campo; Claudio Rapezzi; Francesco Ponticelli; Gian Battista Danzi; Marco Loffi; Gianluca Pontone; Daniele Andreini; Gianni Casella; Gianmarco Iannopollo; Davide Ippolito; Giacomo Bellani; Gianluigi Patelli; Francesca Besana; Claudia Costa; Luigi Vignali; Giorgio Benatti; Mario Iannaccone; Paolo Giacomo Vaudano; Alberto Pacielli; Caterina Chiara De Carlini; Stefano Maggiolini; Pietro Andrea Bonaffini; Michele Senni; Elisa Scarnecchia; Fabio Anastasio; Antonio Colombo; Roberto Ferrari; Antonio Esposito; Francesco Giannini; Marco Toselli
Journal:  Atherosclerosis       Date:  2021-04-07       Impact factor: 5.162

7.  Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities.

Authors:  Marina Rieder; Nadine Gauchel; Siegbert Rieg; Daniel Duerschmied; Klaus Kaier; Carolin Jakob; Stefan Borgmann; Annika Y Classen; Jochen Schneider; Lukas Eberwein; Martin Lablans; Maria Rüthrich; Sebastian Dolff; Kai Wille; Martina Haselberger; Hanno Heuzeroth; Christoph Bode; Constantin von Zur Mühlen
Journal:  Clin Res Cardiol       Date:  2021-09-21       Impact factor: 5.460

8.  Obesity, Inflammation, and Mortality in COVID-19: An Observational Study from the Public Health Care System of New York City.

Authors:  Leonidas Palaiodimos; Ryad Ali; Hugo O Teo; Sahana Parthasarathy; Dimitrios Karamanis; Natalia Chamorro-Pareja; Damianos G Kokkinidis; Sharanjit Kaur; Michail Kladas; Jeremy Sperling; Michael Chang; Kenneth Hupart; Colin Cha-Fong; Shankar Srinivasan; Preeti Kishore; Nichola Davis; Robert T Faillace
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.